Botulinum toxin in the management of facial paralysis

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 23, Issue 4, 2015, Pages 272-280

  Cabin, Jonathan A ^a   Massry, Guy G ^b,c,d   Azizzadeh, Babak ^e,f  

^a NEW YORK EYE AND EAR INFIRMARY   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Beverly Hills Ophthalmic Plastic and Reconstructive Surgery   (United States)

^d Facial Paralysis Institute   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f The Center for Advanced Facial Plastic Surgery   (United States)

Author keywords

Bell's palsy; Botulinum toxin; Facial paralysis; Hyperkinesis; Synkinesis

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

EXERCISE; FACE ASYMMETRY; FACE MUSCLE; FACIAL NERVE PARALYSIS; FLACCID PARALYSIS; FOLLOW UP; HUMAN; HYPERKINESIA; INVOLUNTARY MOVEMENT; NASOLABIAL FOLD; NEUROMODULATION; PHYSIOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYNKINESIS; VOLUNTARY MOVEMENT; CONVALESCENCE; DISEASE MANAGEMENT; FACIAL PARALYSIS;

BOTULINUM TOXINS, TYPE A; DISEASE MANAGEMENT; FACIAL PARALYSIS; HUMANS; NEUROMUSCULAR AGENTS; QUALITY OF LIFE; RECOVERY OF FUNCTION;

EID: 84942752898     PISSN: 10689508     EISSN: 15316998     Source Type: Journal    
DOI: 10.1097/MOO.0000000000000176     Document Type: Review

References (64)

1. Filipo R, Spahiu I, Covelli E, et al. Botulinum toxin in the treatment of facial synkinesis and hyperkinesis. Laryngoscope 2012; 122:266-270.
2. Souayah N, Karim H, Kamin SS, et al. Severe botulism after focal injection of botulinum toxin. Neurology 2006; 67:1855-1856.
3. Peitersen E. Bell's palsy: the spontaneous course of 2500 peripheral facial nerve palsies of different etiologies. Acta Otolaryngol Suppl 2002; (549):4-30.
4. Yamauchi PS, Lowe NJ. Botulinum toxin types A and B: comparison of efficacy, duration, and dose-ranging studies for the treatment of facial rhytides and hyperhidrosis. Clin Dermatol 2004; 22:34-39.
5. Crowner BE, Torres-Russotto D, Carter AR, Racette BA. Systemic weakness after therapeutic injections of botulinum toxin a: a case series and review of the literature. Clin Neuropharmacol 2010; 33:243-247.
6. Pamphlett R. Early terminal and nodal sprouting of motor axons after botulinum toxin. J Neurol Sci 1989; 92:181-192.
7. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991; 324:1186-1194.
8. Varghese-Kroll E, Elovic EP. Contralateral weakness and fatigue after highdose botulinum toxin injection for management of poststroke spasticity. Am J Phys Med Rehabil 2009; 88:495-499.
9. Goldstein EM. Safety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity. J Child Neurol 2006; 21:189-192.
10. Willis AW, Crowner B, Brunstrom JE, et al. High dose botulinum toxin A for the treatment of lower extremity hypertonicity in children with cerebral palsy. Dev Med Child Neurol 2007; 49:818-822.
11. Howell K, Selber P, Graham HK, Reddihough D. Botulinum neurotoxin A: an unusual systemic effect. J Paediatr Child Health 2007; 43:499-501.
12. Kollewe K, Mohammadi B, Dengler R, Dressler D. Hemifacial spasm and reinnervation synkinesias: long-term treatment with either Botox1 or Dysport1. J Neural Transm 2010; 117:759-763.
13. Roggenkämper P, Laskawi R, Damenz W, et al. Involuntary lid closure caused by defective healing of facial paralysis and its treatment with botulinum toxin. Klin Monbl Augenheilkd 1991; 198:268-270.
14. Alster TS, Lupton JR. Botulinum toxin type B for dynamic glabellar rhytides refractory to botulinum toxin type A. Dermatol Surg 2003; 29:516-518.
15. Choi KH, Rho SH, Lee JM, et al. Botulinum toxin injection of both sides of the face to treat postparalytic facial synkinesis. Br J Plast Surg 2013; 66:1058-1063.
16. Hohman MH, Lee LN, Hadlock TA. Two-step highly selective neurectomy for refractory periocular synkinesis. Laryngoscope 2013; 123:1385-1388.
17. Boroojerdi B, Ferbert A, Schwarz M, et al. Botulinum toxin treatment of synkinesia and hyperlacrimation after facial palsy. J Neurol Neurosurg Psychiatr 1998; 65:111-114.
18. Borodic G, Bartley M, Slattery W, et al. Botulinum toxin for aberrant facial nerve regeneration: double-blind, placebo-controlled trial using subjective endpoints. Plast Reconstr Surg 2005; 116:36-43.
19. Armstrong MW, Mountain RE, Murray JA. Treatment of facial synkinesis and facial asymmetry with botulinum toxin type A following facial nerve palsy. Clin Otolaryngol Allied Sci 1996; 21:15-20.
20. Salles AG, Toledo PN, Ferreira MC. Botulinum toxin injection in long-standing facial paralysis patients: improvement of facial symmetry observed up to 6 months. Aesthetic Plast Surg 2009; 33:582-590.
21. Mehta RP, Hadlock TA. Botulinum toxin and quality of life in patients with facial paralysis. Arch Facial Plast Surg 2008; 10:84-87.
22. de Maio MC, Bento RF. Botulinum toxin in facial palsy: an effective treatment for contralateral hyperkinesis. Plast Reconstr Surg 2007; 120:917-927.
23. Crumley RL. Mechanisms of synkinesis. Laryngoscope 1979; 89:1847-1854.
24. Diels HJ. Facial paralysis: is there a role for a therapist? Facial Plast Surg 2000; 16:361-364.
25. Diels HJ, Combs D. Neuromuscular retraining for facial paralysis. Otolaryngol Clin NA 1997; 30:727-743.
26. Diels HJ. Treatment of facial paralysis using electromyographic feedback: a case study. Eur Arch Otorhinolaryngol 1994; S129-S132.
27. Yamamoto E, Nishimura H, Hirono Y. Occurrence of sequelae in Bell's palsy. Acta Otolaryngol Suppl 1988; 446:93-96.
28. Husseman J, Mehta R. Management of synkinesis. Facial Plast Surg 2008; 24:242-249.
29. Malhotra A. Marin-Amat syndrome: a case of acquired facial synkinesis. BMJ Case Rep 2013.
30. McElhinny ER, Reich I, Burt B, et al. Treatment of pseudoptosis secondary to aberrant regeneration of the facial nerve with botulinum toxin type A. Ophthalmic Plast Reconstr Surg 2013; 29:175-178.
31. Laskawi R, Rohrbach S, Rödel R. Surgical and nonsurgical treatment options in patients with movement disorders of the platysma. J Oral Maxillofac Surg 2002; 60:157-162.
32. Moran CJ, Neely JG. Patterns of facial nerve synkinesis. Laryngoscope 1996; 106 (12 Pt 1):1491-1496.
33. Dall'Angelo A, Mandrini S, Sala V, et al. Platysma synkinesis in facial palsy and botulinum toxin type A. Laryngoscope 2014; 124:2513-2517.
34. Montoya FJ, Riddell CE, Caesar R, Hague S. Treatment of gustatory hyperlacrimation (crocodile tears) with injection of botulinum toxin into the lacrimal gland. Eye (Lond) 2002; 16:705-709.
35. Coulson SE, Croxson GR, Adams RD, O'dwyer NJ. Reliability of the 'Sydney,' 'Sunnybrook,' and 'House Brackmann' facial grading systems to assess voluntary movement and synkinesis after facial nerve paralysis. YMHN 2005; 132:543-549.
36. Couch SM, Chundury RV, Holds JB. Subjective and objective outcome measures in the treatment of facial nerve synkinesis with onabotulinumtoxin A (botox). Ophthalm Plast Reconstr Surg 2014; 30:246-250.
37. Mehta RP, WernickRobinson M, Hadlock TA. Validation of the synkinesis assessment questionnaire. Laryngoscope 2007; 117:923-926.
38. Holland NJ, Weiner GM. Recent developments in Bell's palsy. BMJ 2004; 329:553-557.
39. Ross B, Nedzelski JM, McLean JA. Efficacy of feedback training in longstanding facial nerve paresis. Laryngoscope 1991; 101 (7 Pt 1):744-750.
40. Segal B, Hunter T, Danys I, et al. Minimizing synkinesis during rehabilitation of the paralyzed face: preliminary assessment of a new small-movement therapy. J Otolaryngol 1995; 24:149-153.
41. Brach JS, VanSwearingen JM, Lenert J, Johnson PC. Facial neuromuscular retraining for oral synkinesis. Plast Reconstr Surg 1997; 99:1922-1931.
42. Nakamura K, Toda N, Sakamaki K, et al. Biofeedback rehabilitation for prevention of synkinesis after facial palsy. YMHN 2003; 128:539-543.
43. Baricich A, Cabrio C, Paggio R, et al. Peripheral facial nerve palsy: how effective is rehabilitation? Otol Neurotol 2012; 33:1118-1126.
44. Azuma T, Nakamura K, Takahashi M, et al. Mirror biofeedback rehabilitation after administration of single-dose botulinum toxin for treatment of facial synkinesis. Otolaryngol Head Neck Surg 2011; 146:40-45.
45. Monini S, De Carlo A, Biagini M, et al. Combined protocol for treatment of secondary effects from facial nerve palsy. Acta Otolaryngol 2011; 131:882-886.
46. Lee JM, Choi KH, Lim BW, et al. Half-mirror biofeedback exercise in combination with three botulinum toxin A injections for long-lasting treatment of facial sequelae after facial paralysis. J Plast Reconstr Aesthet Surg 2014.
47. Kim J. Contralateral botulinum toxin injection to improve facial asymmetry after acute facial paralysis. Otol Neurotol 2013; 34:319-324.
48. Sadjadpour K. Postfacial palsy phenomena: faulty nerve regeneration or ephaptic transmission? Brain Res 1975; 95:403-406.
49. Keegan DJ, Geerling G, Lee JP, et al. Botulinum toxin treatment for hyperlacrimation secondary to aberrant regenerated seventh nerve palsy or salivary gland transplantation. Br J Ophthalmol 2002; 86:43-46.
50. Hofmann RJ. Treatment of Frey's syndrome (gustatory sweating) and 'crocodile tears' (gustatory epiphora) with purified botulinum toxin. Ophthalm Plast Reconstr Surg 2000; 16:289-291.
51. Riemann R, Pfennigsdorf S, Riemann E, Naumann M. Successful treatment of crocodile tears by injection of botulinum toxin into the lacrimal gland: a case report. Ophthalmology 1999; 106:2322-2324.
52. Nava-Castan?eda A, Tovilla-Canales JL, Boullosa V, et al. Duration of botulinum toxin effect in the treatment of crocodile tears. Ophthalm Plast Reconstr Surg 2006; 22:453-456.
53. Vartanian AJ, Dayan SH. Complications of botulinum toxin A use in facial rejuvenation. Facial Plast Surg Clin North Am 2005; 13:1-10.
54. Borodic GE, Pearce LB, Cheney M, et al. Botulinum A toxin for treatment of aberrant facial nerve regeneration. Plast Reconstr Surg 1993; 91:1042-1045.
55. Marino H, Alurralde A. Spastic facial palsy; peripheral selective neurotomy. Br J Plast Surg 1950; 3:56-59.
56. Dobie RA, Fisch U. Primary and revision surgery (selective neurectomy) for facial hyperkinesia. Arch Otolaryngol Head Neck Surg 1986; 112:154-163.
57. Terzis JK, Karypidis D. Therapeutic strategies in postfacial paralysis synkinesis in adult patients. Plast Reconstr Surg 2012; 129:925e-939e.
58. Guerrissi JO. Selective myectomy for postparetic facial synkinesis. Plast Reconstr Surg 1991; 87:459-466.
59. Dillman DB, Anderson RL. Levator myectomy in synkinetic ptosis. Arch Ophthalmol 1984; 102:422-423.
60. Henstrom DK, Malo JS, Cheney ML, Hadlock TA. Platysmectomy: an effective intervention for facial synkinesis and hypertonicity. Arch Facial Plast Surg 2011; 13:239-243.
61. Mulholland RS. Nonexcisional, minimally invasive rejuvenation of the neck. Clin Plast Surg 2014; 41:11-31.
62. Göschel H, Wohlfarth K, Frevert J, et al. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies -therapeutic consequences. Exp Neurol 1997; 147:96-102.
63. Cavallini M, Cirillo P, Fundarò SP, et al. Safety of botulinum toxin A in aesthetic treatments: a systematic review of clinical studies. Dermatol Surg 2014; 40:525-536.
64. Matarasso SL. Complications of botulinum A exotoxin for hyperfunctional lines. Dermatol Surg 1998; 24:1249-1254.